A Study to Identify and Characterise Patients With Chronic Kidney Disease and Proteinuria

Other illness

• Known NYHA class III or class IV Congestive Heart Failure at the time of enrolment
• Known history of any life-threatening cardiac dysrhythmia (continuous or paroxysmal)
• Known history of solid organ transplantation
• Known history or ongoing allergy/hypersensitivity, as judged by the investigator, to SGLT2i (eg, dapagliflozin, canagliflozin, empagliflozin) or endothelin receptor antagonists (eg, ambrisentan, atrasentan, bosentan)
• Known blood-borne diseases such as specified in Appendix B (category A and B)

Lab values

• Lupus nephritis, anti-neutrophil cytoplasmic autoantibody vasculitis, minimal change disease, autosomal dominant polycystic kidney disease (polycystic kidney disease), Alport syndrome, patients on renal replacement therapy, or clinical nephrotic syndrome with problematic oedema

Other

• Known T1DM
• Known pregnancy at the time for the visit or have an intention to become pregnant

• Male or female aged ≥ 18 years at the time of signing the informed consent
• Express interest to participate in a future CKD clinical study
• eGFR ≥ 20 to \< 90 mL/min/1.73 m2 (eGFRcr\[AS\], Section 8.2.1) (Delgado et al 2022, Inker et al. 2021)
• UACR ≥ 700 mg/g or UPCR ≥ 1000 mg/g based on urine sample at time of screening visit
• Receiving RAS inhibitor therapy (ACEi or ARB) that has been at stable dosing for at least 4 weeks. Exceptions from this requirement will be made for participants who are unable to tolerate RAS inhibitor therapy
• Provision of signed and dated written informed consent before any study-specific procedures